Showing 4161-4170 of 8864 results for "".
- Pinpointing BNP’s Role in ADhttps://practicaldermatology.com/news/pinpointing-bnps-role-in-ad/2462082/The brain natriuretic peptide (BNP) may play a role in activating atopic dermatitis, according to new research in mice. “BNP is expressed in sensory neurons, the neurons responsible for conveying sensation to the brain via the spinal cord,” says Santosh Mishra, associate pro
- Sciton Adds 1064nm Wavelength to mJOULE Platformhttps://practicaldermatology.com/news/sciton-adds-1064nm-wavelength-to-mjoule-platform/2462081/Sciton Inc. is expanding their mJOULE system to include ClearV and ClearSilk to treat vascular lesions and skin discoloration. "The combination of 1064 in the ClearV and ClearSilk delivery systems with the narrowband 532+ BBL filter replaces the need for all other vascular lasers i
- Four Grants Awarded by the GW/Pfizer Global Medical Collaborative Grant Program to Establish Teledermatology Programs in Underserved Communities Across the UShttps://practicaldermatology.com/news/four-grants-awarded-by-the-gwpfizer-global-medical-collaborative-grant-program-to-establish-teledermatology-programs-in-underserved-communities-across-the-us/2462080/The George Washington University (GW) School of Medicine and Health Sciences (SMHS), in collaboration with Pfizer Global Medical Grants, announced the four institutions that will be awarded grants to implement GW’s Teledermatology clinic model in underserved areas across the United States.&
- FDA Approves UCB’s BIMZELX for the Treatment of Adults with Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-ucbs-bimzelx-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis/2462079/The U.S. Food and Drug Administration (FDA) has approved BIMZELX (bimekizumab-bkzx) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Bimekizumab is the first and only approved psoriasis treatment desi
- Exploring OX40’s Role in AD: A Conversation With Dr. Stephan Weidingerhttps://practicaldermatology.com/news/exploring-ox40s-role-in-ad-a-conversation-with-dr-stephan-weidinger/2462078/The anti-Ox40-ligand antibody amlitelimab performed well in the phase 2b Stream-AD trial of adults with moderate-to-severe atopic dermatitis, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. Amlitelimab demonstrated c
- IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanomahttps://practicaldermatology.com/news/ideaya-biosciences-announces-phase-2-expansion-of-darovasertib-and-crizotinib-combination-in-gnaq11-metastatic-cutaneous-melanoma/2462076/IDEAYA Biosciences, Inc. is initiating of a Phase 2 expansion of the darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma. There are currently no U.S Food and Drug Administration-approved therapies for this genetically-defined patient population. Darova
- Almost Half of All Skin Disease Patients Report Sleep Issueshttps://practicaldermatology.com/news/almost-half-of-all-skin-disease-patients-report-sleep-issues/2462075/Almost half of all patients with skin disease report sleep disturbances, finds new research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. The ALL PROJECT analyzed data on more than 50,000 adults across 20 countries to assess the impact
- FDA Approves BMS’ Opdivo (Nivolumab) for Adjuvant Treatment of Eligible Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/fda-approves-bms-opdivo-nivolumab-for-adjuvant-treatment-of-eligible-patients-with-completely-resected-stage-iib-or-iic-melanoma/2462074/The U.S. Food and Drug Administration (FDA) has given its nod to Opdivo (nivolumab) for the adjuvant treatment of eligible adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma. This approval was based on the Phase 3
- Study: Female Adult Acne Patients Face Stigmahttps://practicaldermatology.com/news/study-female-adult-acne-patients-face-stigma/2462073/Faces with acne are seen as less attractive, trustworthy, confident, successful, dominant and happy, and adult female acne has the strongest negative effect, according to research presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. The
- AI in Action: Newest AI Boasts 100% Success Rate in Spotting Melanomashttps://practicaldermatology.com/news/newest-ai-boasts-100-success-rate-in-spotting-melanomas/2462072/The latest artificial intelligence (AI) software reached a 100% detection rate for melanoma, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress in Berlin. The study assessed 22,356 patients with suspected skin cancers over a 2.5-year p